Background/Aims: Neuronostatin, derived from the somatostatin preprohormone, was recently identified to be produced by several tissues exerting a role in cardiovascular regulation and metabolism. Nonetheless, the precise mechanism behind neuronostatinelicited myocardial responses remains elusive. Methods: This study was designed to elucidate the impact of neuronostatin on cardiac contractile function and the underlying mechanism of action involved. Adult male C57 BL/6 mice were subjected to a bolus injection of neuronostatin (50 μg/kg, i.p.). Echocardiographic, cardiomyocyte contractile and intracellular Ca 2+ handling properties were monitored to evaluate the effect of neuronostatin on cardiac function. Western blot analysis was used to examine potential signaling mechanisms involved. Results: Neuronostatin administration suppressed myocardial and cardiomyocyte contractile function and disturbed intracellular Ca 2+ homeostasis. We observed enlarged LVESD (with unchanged LVEDD), reduced fractional shortening, depressed peak shortening, maximal velocity of shortening/relengthening, resting and electrically-stimulated rise in intracellular Ca 2+ , and prolonged relengthening duration in hearts from neuronostatin-treated mice. These effects were accompanied by downregulation of phosphorylation of sarcoplasmic reticulum Ca 2+ -ATPase (SERCA) and phospholamban (PLB) and activation of AMPK. Conclusion: Our data suggest that the cardiac depressant properties of neuronostatin possibly associated with loss of SERCA phosphorylation and AMPK activation. These findings revealed a potent inhibitory capacity for neuronostatin on cardiac function, the physiological relevance of which deserves further study.
Neuronostatin Attenuates Myocardial Contractile Function through Inhibition of Sarcoplasmic Reticulum Ca

2+ -ATPase in Murine Heart
Xiaoling Zhu Somatostatin, a cyclic peptide originally identified as an inhibitor for growth hormone and thyroid-stimulating hormone secretions, plays an important role in gastrointestinal endocrinology [1] and cardiovascular regulation [2] . Somatostatin-like immunoreactivity has been identified in hearts from a number of mammalian species including human [3] . Not surprisingly, somatostatin displays pronounced cardiotropic properties. Somatostatin analogs exert a variety of myocardial morphological, functional and hemodynamic effects in patients with acromegaly [4] . Nonetheless, controversy remains with regards to the cardiac contractile impact of somatostatin analogs. Osadchii and colleagues reported that somatostatin depresses myocardial contractility, diminishes cardiac output and decreases heart rate [3] . In addition, somatostatin suppresses atrial contractile function in isolated guinea-pig hearts [5] . The precise mechanisms underlying the cardiac effects of somatostatin remain elusive.
A novel peptide encoded by the somatostatin gene was recently identified and named neuronostatin [6] . Neuronostatin, a 13-amino acid peptide (Leu-Arg-Gln-Phe-Leu-GlnLys-Ser-Leu-Ala-Ala-Ala-Ala-NH2) reminiscent of somatostatin, is found in central and peripheral organs to play a role in the regulation of hormonal and cardiac function [6, 7] . Neuronostatin has been reported to possess significant roles in a wide variety of biological actions including food intake, drinking behavior and blood pressure. More recent evidence from our group suggested that neuronostatin inhibits cardiac contractile function via a protein kinase A (PKA)-and c-Jun N-terminal kinase (JNK)-dependent mechanism [8] . In addition, neuronostatin attenuates endothelin-1 (ET-1)-induced left ventricular contractility in isolated rat hearts via p38 MAPK and JNK phosphorylation-dependent mechanisms [9] .
Tight control of cytosolic Ca 2+ removal is crucial for the maintenance of normal, cardiac function. Sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a) and its regulator phospholamban (PLB), play an essential role in intracellular Ca 2+ homeostasis and cycling in heart [10, 11] . To this end, the present study was designed to examine the echocardiographic and cardiomyocyte contractile responses of neuronostatin in vivo. /calmodulin-dependent protein kinase II (CaMK II) and troponin I]. We further monitored several key signal pathways such as Akt, AMPdependent kinase (AMPK), extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAPK and JNK, which are reported to mediate neuronostatin-mediated physiological actions [12] .
Materials and Methods
Experimental animal and neuronostatin treatment
The experimental procedures carried out in this study were approved by the University of Wyoming Institutional Animal Use and Care Committee (Laramie, WY, USA) and were in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . In brief, 3-month-old adult male C57BL/6 mice were housed in a temperaturecontrolled environment (22.8 ± 2.0℃, 45-50% humidity) with a 12:12h light/dark cycle with free access to food and tap water. For neuronostatin challenge in vivo, 3-month-old adult C57BL/6 male mice were randomly divided into two groups and to receive neuronostatin (50 μg/kg, i.p.). Cardiac function was evaluated at 3-, 6-, 12-and 18-hr after neuronostatin treatment in the first group of animals. For Western blot analysis, a second cohort of mice were sacrificed under anesthesia (ketamine 80 mg/kg and xylazine 12 mg/kg, i.p.) at 6-hr after neuronostatin injection.
Echocardiographic assessment
Three, six, twelve and eighteen hrs following neuronostatin (50 μg/kg, i.p.) treatment cardiac geometry and function were evaluated in anesthetized (ketamine 80 mg/kg and xylazine 12 mg/kg, i.p.) mice using [13] .
Isolation of murine cardiomyocytes
Murine cardiomyocytes were enzymatically isolated as described [13] . Briefly, under anesthesia (ketamine 80 mg/kg and xylazine 12 mg/kg, i.p.), hearts were removed and perfused with oxygenated (5% CO 2 
Cell shortening and relengthening
Mechanical properties of cardiomyocytes were measured using a SoftEdge MyoCam® system (IonOptix Corporation, Milton, MA). In brief, cardiomyocytes were placed in a chamber mounted onto the stage of an Olympus IX-70 inverted microscope and perfused with a contractile buffer containing: 131 mM NaCl, 4 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose and 10 mM HEPES, at pH 7.4. Cells were field-stimulated with a supra-threshold voltage at a frequency of 0.5 Hz, 3 msec in duration using a pair of platinum wires placed on opposite sides of the chamber connected to an electrical stimulator (FHC stimulator, Brunswick, NE, USA). The cardiomyocytes being studied were displayed on the computer monitor using an IonOptix MyoCam camera and cell length was captured during shortening and relengthening. Cell shortening and relengthening were evaluated using the following indices: peak shortening (PS, indicating peak ventricular contractility), maximal velocity of shortening (+ dL/dt), maximal velocity of relengthening (-dL/dt), time-to-PS (TPS, indicating contraction duration), time-to-90% relengthening (TR 90 , indicating relaxation duration) [14] .
Intracellular Ca2+ fluorescence measurement
Cardiomyocytes were loaded with fura-2/AM (0.5 μM) for 10 min and fluorescence measurements were recorded with a dual-excitation fluorescence photo multiplier system (Ionoptix). Cardiomyocytes were placed on an Olympus IX-70 inverted microscope and observed using Fluor ×40 oil objective. Cells were stimulated at 0.5 Hz and excited at 360 and 380 nm, with fluorescence emissions were detected between 480 and 520 nm by a photomultiplier tube after first illuminating the cells at 360 nm for 0.5 s, then at 380 nm for the duration of the recording. The 360 nm excitation scan was repeated at the end of the protocol, and qualitative changes in intracellular Ca 2+ concentration were inferred from the ratio of fura-2 fluorescence intensity (FFI) at two wavelengths (360/380). Fluorescence decay time was assessed as an indication of the intracellular Ca 2+ clearing rate. Intracellular Ca 2+ transient decay constant was calculated using single and bi-exponential curve fit [15] .
Western blotting
Myocardial proteins were prepared as previously described [15] . Briefly, heart tissues were homogenized using a RIPA lysis buffer, sonicated, and centrifuged at 12,000 xg for 20 min at 4°C. Trisbuffered saline/Tween 20 and protein concentrations of supernatants were measured using the Bradford assay. Samples were separated on a 7%, 10%, 12%,or 15% SDS-PAGE gel in a mini-gel apparatus (Mini-PROTEAN II, Bio-Rad, Hercules, CA, USA) and were then transferred to nitrocellulose membranes (0.2 mm pore size, Bio-Rad). Membranes were blocked for 1 hr in 5% nonfat milk in TBS-Tween and were incubated overnight at 4°C with anti-phospho-Akt (1:1,000), anti-Akt (1:1,000), anti-phospho-AMPK (1:1,000), anti-AMPK (1:1,000), anti--phospho-ERK1/2 (1:1,000), anti-ERK1/2 (1:1,000), anti-phospho-p38MAPK (1:1,000), anti-p38 MAPK (1:1,000), anti-phospho-JNK (1:1,000), anti-JNK (1:1,000), anti-phospho-CaMKII (1:1,000), anti-CaMK II (1:1,000), anti-phospho-Troponin I (1:1,000), anti-Troponin I (1:1,000), antiphospho-Phospholamban pPLB,1:1,000), anti-pPhospholamban (PLB,1:1,000), anti-phospho-SERCA2α
Results
General and echocardiographic properties in mice with or without neuronostatin challenge
Neuronostatin treatment did not affect body and organ weights (heart, liver, kidney and spleen) or size (normalized to body weight) in C57BL/6 mice ( Table 1) . Echocardiographic measurement revealed a remarkable drop in heart rate after 3-, 6-and 12-hr of neuronostatin challenge. In addition, neuronostatin treatment significantly decreased LVESD and fractional shortening without affecting LVEDD between 6 and 12 hrs following neuronostatin challenge, the effect of which returned to basal level 18-hr after neuronostatin treatment (Fig. 1) . 2+ properties To explore the possible mechanism behind neuronostatin-elicited mechanical changes, intracellular Ca 2+ handling was measured using the Fura-2 fluorescence in cardiomyocytes from C57BL/6 mice with or without neuronostatin administration. Our data revealed that neuronostatin significantly decreased resting and electrically stimulated rise in intracellular Ca 2+ (ΔFFI), as well as prolonged intracellular Ca 2+ clearance ( single or bi-exponential) (Fig.  3) .
Effect of neuronostatin on intracellular Ca
Effects of neuronostatin on activation of AMPK and Akt
To further elucidate the signaling mechanism involved in neuronostatin-induced cardiac response, the essential energy fuel signal AMPK and the cell survival mediator Akt were examined in murine hearts following neuronostatin challenge. Results in Fig. 4 
Effect of neuronostatin on intracellular Ca
2+ regulatory proteins To explore the possible mechanism behind neuronostatin-induced myocardial responses, the intracellular Ca 2+ regulatory proteins including SERCA2a, phospholamban and troponin (Fig. 6) .
Effect of AMPK and NOS inhibition on neuronostatin-induced cardiomyocyte responses
To examine the potential involvement of AMPK and NOS in neuronostatin-elicited cardiac response, isolated murine cardiomyocytes were pretreated with the AMPK inhibitor compound C (10 mΜ) [14] or the NOS inhibitor Nϖ-nitro-l-arginine methyl ester (L-NAME, 100 μM) [16] for 30 min prior to neuronostatin challenge (0.3 nM) [8] . Our results showed that compound C and L-NAME both abolished neuronostatin-induced inhibitory effects on PS, ± dL/dt and TR 90 while eliciting little effect on cardiomyocyte mechanics themselves. These data favored a role of AMPK and NOS in neuronostatin-induced cardiac responses (Fig. 7) .
Discussion
Neuronostatin was originally identified as a novel peptide encoded by the somatostatin gene. The salient findings from our current study revealed that the newly identified peptide , as well as prolonged duration of relengthening. These findings support the previous report that neuronostatin produces Fig. 6 . Effect of neuronostatin-induced changes in intracellular Ca 2+ regulatory proteins. A: Representative gel bots depicting expression of phospho-SERCA2a, SERCA2a, phospho-phospholamban(PLB, 5 kDa) , phospholamban (5 kDa), phospho-troponin I, troponin I, phospho-CaMK II, CaMK II and GAPDH (loading control); B. phospho-SERCA2a;C. pan SERCA2a; D Phospho-SERCA2a-to-SERCA2a ratio; E. phospho-PLB; F.pan PLB; G. Phospho-PLB-to-PLB ratio; H.SERCA2a/ PLB; I.phospho-Troponin; J pan Troponin I;K. Phospho-Troponin I-to-Troponin I ratio; L .phospho-CaMK II;M. Phospho-CaMK II-to-CaMK II ratio.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry overt cardiac depressant action in vitro [8] . Moreover, our present findings revealed that neuronostatin-elicited cardiac depression may be mediated, at least in part, through AMPK as inhibition of AMPK using compound C effectively ablated neuronostatin-induced cardiac response. Meanwhile, the inhibitory effect of neuronostatin was causally associated with decreased SERCA2a and SERCA2a-to-phospholamban ratio, as well as phosphorylation of the SERCA inhibitory protein phospholamban (favoring a better SERCA activity). A greater phosphorylation of troponin I was also involved in the neuronostatin-mediated cardiac depression and intracellular Ca 2+ mishandling. Our results did not favor any involvement of ERK1/2, p38 MAPK and JNK in neuronostatin-induced cardiac dysfunction. These observations suggest that endogenous neuronostatin, originating in cardiac afferents, may exert negative regulatory action on myocardial contractile function.
Observation from our study revealed impaired intracellular Ca 2+ handling in particular decreased ΔFFI and prolonged intracellular Ca 2 + decay following neuronostatin treatment, which may be attributed to defective contractile and intracellular Ca 2+ transport/regulatory proteins [17] , reduced intracellular Ca 2+ availability resulted from poor SR Ca 2+ load [18] , and altered myofilament Ca 2+ sensitivity [19] . Ample evidence has depicted that defects in SR Ca 2+ handling are related with attenuated contractility [17, 18, 20] . SERCA2a is a cellular component governing regulation of SR Ca 2+ cycling (including cytosolic Ca 2+ removal and SR Ca 2+ load), en route to fine maintenance of myocardial contraction and relaxation [18, 20] . 
Phospholamban serves as an endogenous inhibitor of SERCA2 to compromise the SERCA2a affinity for Ca 2+ [10, 17, 21] . Our data revealed down-regulated total and phosphorylation of SERCA2a in conjunction with unchanged phospholamban pan protein expression and phosphorylation following neuronostatin exposure. The reduced SERCA2a level and SERCA2a/PLB ratio may account for, at least in part, intracellular Ca 2+ mishandling and impaired relaxation (prolongation in relengthening duration and intracellular Ca 2+ clearing). Cardiac troponin I (cTnI) is the key inhibitory element of the troponin complex, which regulates Ca 2+ sensitivity and myocardial contraction [22] . Enhanced phosphorylation of troponin I following neuronostatin challenge suggests a loss in myofilament Ca 2+ sensitivity in response to neuronostatin challenge. Troponin I (Ser 23 /24 ) is phosphorylated by associated with PKA-dependent phosphorylation, which decreases myofilament Ca 2+ sensitivity by reducing the Ca 2+ binding affinity for TnC [23] . Ca 2+ /Calmodulin-dependent protein kinase II (CaMKII) is considered another master regulator for intracellular Ca 2+ cycling through its phosphorylation of phospholamban and RYR [24] . However, data from our current study did not favor a major role for CaMK II in neuronostatin exposure-induced cardiac response.
Our finding revealed that AMPK inhibition using compound C effectively negated neuronostatin-induced cardiac depressant responses, suggesting a role for AMPK in neuronostatin-induced cardiac action. AMPK, as a key energy sensor, is activated under conditions that deplete cellular ATP and elevate AMP levels response to energy deprivation in the heart, such as in heart failure [25] . AMPK may also be activated by hormones such as leptin and ghrelin [26, 27] . More importantly, inhibition of AMPK by compound C has been reported to slightly potentiate somatotrophic response to growth hormone-releasing hormone (GHRH) [28] . In our hands, neuronostatin augmented AMPK phosphorylation along with unchanged Akt phosphorylation. We suggest that neuronostatin may interrupt energy and metabolic balance, leading to decreased ATP availability, enhanced AMP/ATP ratio to turn on AMPK in the heart.
Recent evidence has identified a role for MAPK including ERK1/2, p38 MAPK and JNK involved in harmful cellular responses such as oxidative stress, DNA damage, hyperosmosis, low osmolarity and infection [29, 30] . In the heart, ERK1/2, p38 MAPK and JNK serve as important regulators for cardiac hypertrophy, interstitial fibrosis and cell survival [31, 32] . Somatostatin, a growth hormone inhibitory peptide, has been shown to play a key role in regulation of cell proliferation through modulation of MAPKs and cell survival pathway [33] . Findings from our current study do not favor a major role of stress signaling cascades including p38 MAPK and JNK in neuronostatin-elicited cardiomyocyte response in vivo, with the exception of ERK1/2. Although the precise mechanism responsible for the enhanced ERK1/2 phosphorylation in response to neuronostatin is unknown at this time, it may be related to a compensatory response to neuronostatin-induce pharmacological stress in the heart.
In conclusion, our current study demonstrated that neuronostatin attenuates myocardial contractile function and intracellular Ca 2+ mishandling. The neuronostatin-elicited cardiac depression may be mediated, at least in part, through AMPK activation, loss of SERCA2a levels and SERCA2a-to-phospholamban ratio. These findings revealed not only a potent inhibitory capacity for neuronostatin on cardiac function, but also new insights for signaling mechanisms involved in neuronostatin-induced cardiac contractile anomalies. At this point, the precise mechanism responsible for neuronostatin-induced cardiac pathophysiological changes still remains elusive. Further studies should focus on better elucidation of cellular processes governing neuronostatin-induced biological effects.
